Pfizer announced on September 28 that it will present data from 45 abstracts at the European Society for Medical Oncology (ESMO) Congress 2026, held October 23-27 in Madrid. The abstracts include company-sponsored, investigator-sponsored, and collaborative studies. Eleven will be oral presentations.
The company said the program focuses on breast cancer, genitourinary cancers, and lung cancer. It covers established medicines, including PADCEV (enfortumab vedotin-ejfv) and TALZENNA (talazoparib), and late-stage pipeline candidates such as atirmociclib and tivunatamig (PF-08634404). Pfizer’s Chief Oncology Officer, Jeff Legos, said:
“We’re focused on improving outcomes for people living with cancer. That means continuing to raise the standard of care today while pursuing the breakthroughs that will shape the future of oncology.”
The announcement is a preview. It describes the studies and schedules but does not report efficacy or safety results, which will be presented at the congress. Times below are in CET.
Lung Cancer
Sigvotatug vedotin (SV) in previously treated non-squamous NSCLC
Late-breaking overall survival (OS) and progression-free survival (PFS) data will come from the Phase 3 SigVie-002 study. It evaluates SV, an investigational integrin β6-directed antibody-drug conjugate, against docetaxel. Pfizer said the analysis adds to topline results it announced earlier and will inform development in earlier treatment settings. These include an ongoing Phase 3 trial of SV with pembrolizumab in first-line advanced NSCLC.
Abstract LBA68: Phase 3 study of sigvotatug vedotin (SV) vs docetaxel in previously treated non-squamous non-small cell lung cancer (NSCLC)
Presenter: Peters et al
Session: Proffered Paper 1, October 25, 10:15–11:45
Tivunatamig plus chemotherapy in first-line NSCLC
Updated Phase 2 data will cover tivunatamig, a bispecific antibody targeting PD-1 and VEGF, combined with chemotherapy in first-line PD-L1-expressing NSCLC. Pfizer is developing the agent across tumor types. Pivotal studies are ongoing in first-line NSCLC, first-line metastatic colorectal cancer, and advanced or recurrent endometrial cancer. Planned Phase 3 combination studies include one with PADCEV in metastatic urothelial cancer.
Abstract 2660P: Phase 2 trial of the PD-1/VEGF bispecific antibody, PF-08634404 (SSGJ-707), plus chemotherapy (chemo) in advanced NSCLC: Updated results
Presenter: Wu et al
Session: Poster Presentation, October 26, 12:00–12:45
Breast Cancer
Atirmociclib plus fulvestrant after CDK4/6 inhibitor therapy
Randomized Phase 2 results from the FOURLIGHT-1 study will be presented. It evaluates atirmociclib, a highly selective CDK4 inhibitor, with fulvestrant in HR-positive, HER2-negative advanced or metastatic breast cancer after prior CDK4/6 inhibitor-based treatment. Pfizer said the results support atirmociclib as a potential first-in-class cell cycle inhibitor backbone in this setting. A Phase 3 study in frontline metastatic disease is ongoing. Another Phase 3 study in early breast cancer is planned, combining atirmociclib with giredestrant, an investigational oral selective oestrogen receptor degrader being developed by Roche.
Abstract 1842O: Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK 4/6 inhibitor (CDK 4/6i) in a randomized phase 2 study (FOURLIGHT-1)
Presenter: Giordano et al
Session: Proffered Paper Session, October 24, 08:30–10:00
Quality of life in HER2-positive disease
A health-related quality of life analysis from the Phase 3 HER2CLIMB-05 study will also be presented. The study evaluates tucatinib versus placebo with trastuzumab and pertuzumab as first-line maintenance therapy in HER2-positive metastatic breast cancer.
Abstract 1766RO: Health-related quality of life from HER2CLIMB-05: A Phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
Presenter: Dieras et al
Session: Proffered Paper Session, October 24, 10:15–11:45
Genitourinary Cancers
Bladder and Urothelial Cancer
EV-302 exploratory analyses
Two posters will present updated exploratory analyses from the Phase 3 EV-302 trial of PADCEV plus pembrolizumab in previously untreated locally advanced or metastatic urothelial carcinoma. One covers older patients and those with comorbidities. The other covers subgroups defined by disease-related characteristics. Pfizer said the findings support the regimen as a first-line foundation of care across clinically relevant populations.
Abstract 4761P: Enfortumab vedotin plus pembrolizumab (EV+P) for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Updated exploratory analysis of EV-302 in older patients (pts) and those with comorbidities
Presenter: Sridhar et al
Abstract 4760P: Enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Exploratory analyses based on disease-related characteristics from EV-302
Presenter: Bedke et al
Session: Poster Presentations, October 23, 15:15–16:00
Perioperative therapy in muscle-invasive bladder cancer (MIBC)
Three presentations address perioperative PADCEV plus pembrolizumab, which Pfizer described as a potential new standard of care. Two are Proffered Paper sessions on October 23 at 13:30–15:00, and the third is on October 24. All three are marked as MSD-led in the program.
Abstract 4733O: Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in patients (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: Ad hoc analysis from KEYNOTE-905 (EV-303)
Presenter: Ullén et al
Abstract 4734O: ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with MIBC who are eligible for cisplatin
Presenter: Chatzkel et al
Abstract 4738RO: Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with MIBC eligible for cisplatin in the phase 3 KEYNOTE-B15 study
Presenter: Gómez De Liaño et al
Session: Proffered Paper Session, October 24, 10:15–11:45
Pfizer and Astellas have a clinical collaboration with Merck to evaluate PADCEV and KEYTRUDA (pembrolizumab) in previously untreated metastatic urothelial cancer and MIBC, regardless of cisplatin eligibility.
Prostate Cancer
TALAPRO-3 in HRR-altered mCSPC
Three abstracts come from the Phase 3 TALAPRO-3 study of talazoparib plus enzalutamide versus placebo plus enzalutamide. It enrolled men with homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer. Pfizer said a supplemental New Drug Application for the combination in this setting is under Priority Review by the U.S. Food and Drug Administration (FDA).
Abstract 2219RO: Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3
Presenter: Azad et al
Abstract 2222RO: Patient-reported outcomes (PROs) in men with mCSPC and HRR gene alterations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from the Phase 3 TALAPRO-3 study
Presenter: Azad et al
Session (both): Rapid Oral Session, October 23, 13:30–15:00
Abstract 2231P: Talazoparib (TALA) + enzalutamide (ENZA) in patients (pts) with mCSPC with HRR gene alterations: Safety analyses from the Phase 3 TALAPRO-3 study
Presenter: Mateo et al
Session: Poster Presentation, October 23, 15:15–16:00
Mevrometostat in mCRPC
A poster will present safety and efficacy data for mevrometostat monotherapy in metastatic castration-resistant prostate cancer. It does not appear in Pfizer’s list of key highlights.
Abstract 2296P: Safety and efficacy of mevrometostat monotherapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: J. Carles Galceran et al
Session: Poster Presentation, October 23, 15:15–16:00
Melanoma
STARBOARD triplet regimen
Results will be presented from STARBOARD, a non-registrational Phase 3 trial. It evaluates BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) with pembrolizumab versus placebo with pembrolizumab in first-line unresectable locally advanced or metastatic BRAF V600-mutant melanoma. Pfizer said the findings contribute to an evolving treatment landscape.
Abstract 2071O: STARBOARD Phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (PBO) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
Presenter: Schadendorf et al
Session: Proffered Paper Session, October 23, 16:15–17:45
Pfizer’s ESMO 2026 program spans four tumor types and includes late-breaking, oral, and poster presentations. Lung cancer data center on sigvotatug vedotin and tivunatamig. Breast cancer data center on atirmociclib. The genitourinary program combines perioperative and first-line PADCEV data in bladder cancer with TALAPRO-3 analyses in prostate cancer. The melanoma program presents the STARBOARD triplet regimen. The company has not yet released efficacy or safety findings for most of these studies. The data are scheduled for presentation in Madrid between October 23 and 27.
ESMO Congress 2026
The ESMO Congress is the annual meeting of the European Society for Medical Oncology. It is described by organizers as a leading oncology platform for doctors, researchers, patient advocates, journalists and healthcare industry representatives from around the world. The 2026 edition is scheduled for October 23 to 27 at IFEMA MADRID in Spain.
Congress President Fabrice André leads the 2026 meeting, alongside Scientific Co-Chairs Yelena Janjigian and James Larkin and Educational Chair Nadia Harbeck. The congress will offer both an in-person program and a virtual option. More than 296 scientific, educational, poster and networking sessions will be streamed live through the Virtual Congress Platform.
Stay tuned to OncoDaily for comprehensive coverage of ESMO 2026 and the latest oncology updates.
